Whalesbook
New Liver Drug Development for India
Torrent Pharmaceuticals is preparing to introduce Resmetirom, a promising new treatment for metabolic dysfunction-associated steatohepatitis (MASH), into the Indian market. This drug, already approved in the United States as Rezdiffra by Madrigal Pharmaceuticals, is currently in Phase 3 clinical trials in India. Torrent's Managing Director, Aman Mehta, stated that if trials are successful, the company could be among the first to offer this innovative therapy in India once patent protections end. This initiative is seen as a major growth opportunity, especially since India currently lacks novel treatments for MASH, a serious liver condition linked to metabolic health issues. Torrent expects to potentially launch the drug 12 to 18 months after the patent expires, contingent on positive trial outcomes and regulatory approvals.
Semaglutide Success Boosts Market Position
Alongside its MASH drug plans, Torrent Pharmaceuticals has achieved significant success with its branded semaglutide products, Semalix (oral) and Sembolic (injectable), in India. The company quickly gained a leading position in the generic market. According to Pharmatrac data for April, Torrent held a 38% share of the Indian generic semaglutide market, with 28% in injectables and 100% in oral formulations. Despite expecting new competition, particularly in the oral segment, Torrent attributes its strong prescription momentum to being an early provider of both oral and injectable semaglutide.
Market Performance and Competitive Insights
Torrent Pharmaceuticals is drawing comparisons between its semaglutide opportunity and its successful launch of sitagliptin, a diabetes drug, in 2023. Sitagliptin generated around ₹70-75 crore in its first year and captured a 20-22% share of the generic diabetes market, which Mehta described as a typical, though successful, generic launch. In contrast, semaglutide is projected to generate ₹200-250 crore, highlighting a much larger market potential for treatments addressing metabolic and chronic diseases. Insights gained from its US experience with Madrigal Pharmaceuticals' Rezdiffra will be valuable for the Indian launch, aiding in understanding the treatment landscape and physician acceptance. While not explicitly named, Torrent is aware of major competitors like Novo Nordisk's Ozempic and Wegovy, using this intelligence to plan its market entry and gain share in India.
Outlook for Future Growth
The estimated market size for semaglutide in India over the next three to five years is speculative but expected to exceed any previous drug launch for Torrent. The company's ability to successfully navigate clinical trials, secure regulatory clearances, and compete effectively in both the new MASH drug market and the dynamic semaglutide segment will be crucial. Investors will be monitoring Torrent's financial performance, including its P/E ratio and market capitalization, as it invests in these upcoming products.